Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Host pro-viral factors in Aedes aegypti are a diverse group of mosquito-encoded proteins and cellular pathways that are essential for the replication and transmission of human-pathogenic arboviruses, including Dengue (DENV), Zika (ZIKV), and Chikungunya (CHIKV) [Sessions et al., 2009, Nature]. These factors are exploited by viruses at various stages of the infection cycle, such as the Vacuolar-type H+-ATPase (V-ATPase) which facilitates endosomal acidification for viral entry, and Exportin-1 (XPO1) which mediates the nucleocytoplasmic transport of viral components [Angleró-Rodríguez et al., 2017, PLoS NTD; Botting et al., 2021, Antiviral Res.]. Other critical factors include ribosomal proteins like RACK1, which are necessary for the translation of the viral polyprotein, and RNA-binding proteins like Loquacious that support viral RNA synthesis [Lin et al., 2015, J. Virol.; Haac et al., 2015, J. Virol.]. Targeting these host factors, either through small-molecule inhibitors or genetic engineering (e.g., CRISPR-based gene drives), aims to reduce vector competence and block the transmission of diseases to human populations [Gantz et al., 2015, PNAS]. However, this strategy faces significant hurdles, including the potential for reduced mosquito fitness and the ecological consequences of altering mosquito populations. Furthermore, the diversity of host factors utilized by different viruses necessitates the identification of conserved hub factors to ensure broad-spectrum efficacy against multiple circulating arboviruses.
Inhibition of mosquito cellular machinery and pathways required for the viral life cycle, including entry, replication, and assembly, to block transmission.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Host pro-viral factors in Aedes aegypti.